Date: 2012-05-16
Type of information:
phase: 1
Announcement: completion of the dose ranging Phase I section
Company: Ark Therapeutics (UK)
Product: VEGF-D adenoviral vector
Action mechanism: Refractory angina is a consequence of insufficient blood supply to the areas of heart muscle damaged by a heart attack. Ark\'s adenoviral vector carrying a transgene for expression of pro-angiogenic human VEGF-D is designed to treat the condition by stimulating new blood vessel generation at the ischemic heart muscle to which it is directly administered.
Disease: refractory angina
Therapeutic area: Cardiovascular diseases
Country:
Trial details:
Latest
news: Ark Therapeutics has announced the completion of the dose ranging Phase I section of the academic study of Ark\'s VEGF-D adenoviral vector treatment for refractory angina. The study is being carried out in collaboration with the AIV Institute in Finland.
The subsequent Phase IIa controlled efficacy stage will comprise 15 additional patients to be treated with the optimal dose identified from Phase I and will also compare with controls for indicators of both safety and efficacy. The Phase IIa stage is expected to enrol its first patient in Q3 2012.
